EASL 2014: Sofosbuvir + Ribavirin Safe and Effective for Hepatitis C Patients with Advanced Liver Disease
- Category: Experimental HCV Drugs
- Published on Tuesday, 15 April 2014 00:00
- Written by Liz Highleyman
Sofosbuvir (Sovaldi) plus ribavirin is a safe option that can lead to sustained response for people with advanced liver disease including those with decompensated cirrhosis and portal hypertension and patients who experience severe hepatitis recurrence after a liver transplant, researchers reported last week at the 49thEASL International Liver Congress in London.